A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

Article ID	Journal	Published Year	Pages	File Type
10962674	Vaccine	2016	8 Pages	PDF

Abstract

The safety and immunogenicity results from this study support inclusion of the GLA-SE adjuvant in this RSV vaccine for older adults and also support assessment of the efficacy of the vaccine in a larger clinical trial. Clinicaltrials.gov NCT02115815.

Keywords

GLA-SE SFC GLA IFN-γ ELISPOT TLR-4 PCA Adjuvant Stable emulsion Cell-mediated immunity Enzyme-linked immunospot adult Enzyme-linked immunosorbent assay ELISA spot forming cells Vaccine Respiratory syncytial virus Interferon gamma Toll-like receptor-4

Related Topics

Life Sciences Immunology and Microbiology Immunology

Preview

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

Authors

Judith Falloon, Fei Ji, Craig Curtis, Stephan Bart, Eric Sheldon, Diane Krieger, Filip Dubovsky, Stacie Lambert, Therese Takas, Tonya Villafana, Mark T. Esser,